Loading…
Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase in two tertiary-care teaching hospitals
Objectives: To assess risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase (MBL-PA) in two teaching hospitals where horizontal dissemination has been demonstrated. Methods: A case–control study was performed in both hospitals (assigned as hospital 1 and...
Saved in:
Published in: | Journal of antimicrobial chemotherapy 2006-10, Vol.58 (4), p.882-885 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 885 |
container_issue | 4 |
container_start_page | 882 |
container_title | Journal of antimicrobial chemotherapy |
container_volume | 58 |
creator | Zavascki, Alexandre Prehn Barth, Afonso Luís Gaspareto, Patrick Barcelos Gonçalves, Ana Lúcia Saraiva Moro, Ana Lúcia Didonet Fernandes, Juliana Fernandez Goldani, Luciano Zubaran |
description | Objectives: To assess risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase (MBL-PA) in two teaching hospitals where horizontal dissemination has been demonstrated. Methods: A case–control study was performed in both hospitals (assigned as hospital 1 and 2). Cases were patients with MBL-PA infections and controls were those with non-MBL-PA infections. Multivariate analysis was performed to identify independent risk factors. Results: A total of 86 cases and 212 controls were included in the study. A logistic regression model showed that exposure to β-lactams [odds ratio (OR) 3.21; 95% confidence interval (CI) 1.74–5.93] or fluoroquinolones (OR 3.50; 95% CI 1.46–8.37) was associated with MBL-PA infections. Other independent risk factors were neurological disease (OR 3.00; 95% CI 1.61–5.58), urinary tract infection (OR 2.48; 95% CI 1.21–5.09) and renal failure (OR 2.29; 95% CI 1.13–4.65). Admission to hospital 1 (OR 5.97; 95% CI 3.45–14.09) and intensive care unit stay (OR 2.07; 95% CI 1.46–3.96) were also associated with increased risk for MBL-PA infections. Conclusions: β-Lactam exposure is an important risk factor for MBL-PA infections even in a setting where patient-to-patient transmission plays a major role in the spread of the isolates. Other risk factors deserve further investigation, particularly exposure to fluoroquinolones. |
doi_str_mv | 10.1093/jac/dkl327 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68838664</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68838664</sourcerecordid><originalsourceid>FETCH-LOGICAL-i308t-49c934637b9a38ae171e11a3b4e0fe0ba3218286bc7a99343318d1d728ffbb9f3</originalsourceid><addsrcrecordid>eNqF0Mtu1DAUgGELgehQ2PAAyBvYmfqS-LJEFUyRKlFuYsQmOnHs1p0kntqOgGfo2_RBeCZMO8CS1Vn4O79sI_SU0ZeMGnF0CfZo2I6Cq3toxRpJCaeG3UcrKmhLVNOKA_Qo50tKqWylfogOmNSmNUKu0PWHkLfYgy0xZexjwnPM0cYpwIjD7J0tIc4ZD4vDJeKz7JYhTnGGjMGl5TxUDniX4rDYMJ_jyRUYx0h-3pCxRmGC7GoHl28RF5dKgPSDWEi15sBe_F65iHkX6lZ-jB74OtyT_TxEn9-8_nR8Qk7frd8evzolQVBdSGOsEY0UqjcgNDimmGMMRN846h3tQXCmuZa9VWCqFILpgQ2Ka-_73nhxiF7cdeu1rxaXSzeFbN04wuzikjuptdBSNv-FzAjOmeIVPtvDpZ_c0O1SmOpDuz__XMHzPYBsYfQJZhvyP6dZ26jbELlzIRf3_e85pG0nlVBtd7L52q3X_Euz-fi-24hfy_GfaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19322172</pqid></control><display><type>article</type><title>Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase in two tertiary-care teaching hospitals</title><source>Oxford Journals Online</source><creator>Zavascki, Alexandre Prehn ; Barth, Afonso Luís ; Gaspareto, Patrick Barcelos ; Gonçalves, Ana Lúcia Saraiva ; Moro, Ana Lúcia Didonet ; Fernandes, Juliana Fernandez ; Goldani, Luciano Zubaran</creator><creatorcontrib>Zavascki, Alexandre Prehn ; Barth, Afonso Luís ; Gaspareto, Patrick Barcelos ; Gonçalves, Ana Lúcia Saraiva ; Moro, Ana Lúcia Didonet ; Fernandes, Juliana Fernandez ; Goldani, Luciano Zubaran</creatorcontrib><description>Objectives: To assess risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase (MBL-PA) in two teaching hospitals where horizontal dissemination has been demonstrated. Methods: A case–control study was performed in both hospitals (assigned as hospital 1 and 2). Cases were patients with MBL-PA infections and controls were those with non-MBL-PA infections. Multivariate analysis was performed to identify independent risk factors. Results: A total of 86 cases and 212 controls were included in the study. A logistic regression model showed that exposure to β-lactams [odds ratio (OR) 3.21; 95% confidence interval (CI) 1.74–5.93] or fluoroquinolones (OR 3.50; 95% CI 1.46–8.37) was associated with MBL-PA infections. Other independent risk factors were neurological disease (OR 3.00; 95% CI 1.61–5.58), urinary tract infection (OR 2.48; 95% CI 1.21–5.09) and renal failure (OR 2.29; 95% CI 1.13–4.65). Admission to hospital 1 (OR 5.97; 95% CI 3.45–14.09) and intensive care unit stay (OR 2.07; 95% CI 1.46–3.96) were also associated with increased risk for MBL-PA infections. Conclusions: β-Lactam exposure is an important risk factor for MBL-PA infections even in a setting where patient-to-patient transmission plays a major role in the spread of the isolates. Other risk factors deserve further investigation, particularly exposure to fluoroquinolones.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkl327</identifier><identifier>PMID: 16895936</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Anti-Bacterial Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; bacterial drug resistance ; beta-Lactamases - biosynthesis ; beta-Lactams - therapeutic use ; Biological and medical sciences ; Case-Control Studies ; Cross Infection - drug therapy ; Cross Infection - epidemiology ; Cross Infection - microbiology ; Female ; fluoroquinolones ; Fluoroquinolones - therapeutic use ; Hospitals, Teaching ; Humans ; Incidence ; Male ; Medical sciences ; Middle Aged ; multiple bacterial drug resistance ; P. aeruginosa ; Pharmacology. Drug treatments ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - enzymology ; Pseudomonas Infections - drug therapy ; Pseudomonas Infections - epidemiology ; Pseudomonas Infections - microbiology ; Risk Factors ; SPM-1 β-lactamase ; β-lactamases</subject><ispartof>Journal of antimicrobial chemotherapy, 2006-10, Vol.58 (4), p.882-885</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18154772$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16895936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zavascki, Alexandre Prehn</creatorcontrib><creatorcontrib>Barth, Afonso Luís</creatorcontrib><creatorcontrib>Gaspareto, Patrick Barcelos</creatorcontrib><creatorcontrib>Gonçalves, Ana Lúcia Saraiva</creatorcontrib><creatorcontrib>Moro, Ana Lúcia Didonet</creatorcontrib><creatorcontrib>Fernandes, Juliana Fernandez</creatorcontrib><creatorcontrib>Goldani, Luciano Zubaran</creatorcontrib><title>Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase in two tertiary-care teaching hospitals</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Objectives: To assess risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase (MBL-PA) in two teaching hospitals where horizontal dissemination has been demonstrated. Methods: A case–control study was performed in both hospitals (assigned as hospital 1 and 2). Cases were patients with MBL-PA infections and controls were those with non-MBL-PA infections. Multivariate analysis was performed to identify independent risk factors. Results: A total of 86 cases and 212 controls were included in the study. A logistic regression model showed that exposure to β-lactams [odds ratio (OR) 3.21; 95% confidence interval (CI) 1.74–5.93] or fluoroquinolones (OR 3.50; 95% CI 1.46–8.37) was associated with MBL-PA infections. Other independent risk factors were neurological disease (OR 3.00; 95% CI 1.61–5.58), urinary tract infection (OR 2.48; 95% CI 1.21–5.09) and renal failure (OR 2.29; 95% CI 1.13–4.65). Admission to hospital 1 (OR 5.97; 95% CI 3.45–14.09) and intensive care unit stay (OR 2.07; 95% CI 1.46–3.96) were also associated with increased risk for MBL-PA infections. Conclusions: β-Lactam exposure is an important risk factor for MBL-PA infections even in a setting where patient-to-patient transmission plays a major role in the spread of the isolates. Other risk factors deserve further investigation, particularly exposure to fluoroquinolones.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>bacterial drug resistance</subject><subject>beta-Lactamases - biosynthesis</subject><subject>beta-Lactams - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - epidemiology</subject><subject>Cross Infection - microbiology</subject><subject>Female</subject><subject>fluoroquinolones</subject><subject>Fluoroquinolones - therapeutic use</subject><subject>Hospitals, Teaching</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>multiple bacterial drug resistance</subject><subject>P. aeruginosa</subject><subject>Pharmacology. Drug treatments</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - enzymology</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Pseudomonas Infections - epidemiology</subject><subject>Pseudomonas Infections - microbiology</subject><subject>Risk Factors</subject><subject>SPM-1 β-lactamase</subject><subject>β-lactamases</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqF0Mtu1DAUgGELgehQ2PAAyBvYmfqS-LJEFUyRKlFuYsQmOnHs1p0kntqOgGfo2_RBeCZMO8CS1Vn4O79sI_SU0ZeMGnF0CfZo2I6Cq3toxRpJCaeG3UcrKmhLVNOKA_Qo50tKqWylfogOmNSmNUKu0PWHkLfYgy0xZexjwnPM0cYpwIjD7J0tIc4ZD4vDJeKz7JYhTnGGjMGl5TxUDniX4rDYMJ_jyRUYx0h-3pCxRmGC7GoHl28RF5dKgPSDWEi15sBe_F65iHkX6lZ-jB74OtyT_TxEn9-8_nR8Qk7frd8evzolQVBdSGOsEY0UqjcgNDimmGMMRN846h3tQXCmuZa9VWCqFILpgQ2Ka-_73nhxiF7cdeu1rxaXSzeFbN04wuzikjuptdBSNv-FzAjOmeIVPtvDpZ_c0O1SmOpDuz__XMHzPYBsYfQJZhvyP6dZ26jbELlzIRf3_e85pG0nlVBtd7L52q3X_Euz-fi-24hfy_GfaQ</recordid><startdate>20061001</startdate><enddate>20061001</enddate><creator>Zavascki, Alexandre Prehn</creator><creator>Barth, Afonso Luís</creator><creator>Gaspareto, Patrick Barcelos</creator><creator>Gonçalves, Ana Lúcia Saraiva</creator><creator>Moro, Ana Lúcia Didonet</creator><creator>Fernandes, Juliana Fernandez</creator><creator>Goldani, Luciano Zubaran</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20061001</creationdate><title>Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase in two tertiary-care teaching hospitals</title><author>Zavascki, Alexandre Prehn ; Barth, Afonso Luís ; Gaspareto, Patrick Barcelos ; Gonçalves, Ana Lúcia Saraiva ; Moro, Ana Lúcia Didonet ; Fernandes, Juliana Fernandez ; Goldani, Luciano Zubaran</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i308t-49c934637b9a38ae171e11a3b4e0fe0ba3218286bc7a99343318d1d728ffbb9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>bacterial drug resistance</topic><topic>beta-Lactamases - biosynthesis</topic><topic>beta-Lactams - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - epidemiology</topic><topic>Cross Infection - microbiology</topic><topic>Female</topic><topic>fluoroquinolones</topic><topic>Fluoroquinolones - therapeutic use</topic><topic>Hospitals, Teaching</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>multiple bacterial drug resistance</topic><topic>P. aeruginosa</topic><topic>Pharmacology. Drug treatments</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - enzymology</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Pseudomonas Infections - epidemiology</topic><topic>Pseudomonas Infections - microbiology</topic><topic>Risk Factors</topic><topic>SPM-1 β-lactamase</topic><topic>β-lactamases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zavascki, Alexandre Prehn</creatorcontrib><creatorcontrib>Barth, Afonso Luís</creatorcontrib><creatorcontrib>Gaspareto, Patrick Barcelos</creatorcontrib><creatorcontrib>Gonçalves, Ana Lúcia Saraiva</creatorcontrib><creatorcontrib>Moro, Ana Lúcia Didonet</creatorcontrib><creatorcontrib>Fernandes, Juliana Fernandez</creatorcontrib><creatorcontrib>Goldani, Luciano Zubaran</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zavascki, Alexandre Prehn</au><au>Barth, Afonso Luís</au><au>Gaspareto, Patrick Barcelos</au><au>Gonçalves, Ana Lúcia Saraiva</au><au>Moro, Ana Lúcia Didonet</au><au>Fernandes, Juliana Fernandez</au><au>Goldani, Luciano Zubaran</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase in two tertiary-care teaching hospitals</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2006-10-01</date><risdate>2006</risdate><volume>58</volume><issue>4</issue><spage>882</spage><epage>885</epage><pages>882-885</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Objectives: To assess risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase (MBL-PA) in two teaching hospitals where horizontal dissemination has been demonstrated. Methods: A case–control study was performed in both hospitals (assigned as hospital 1 and 2). Cases were patients with MBL-PA infections and controls were those with non-MBL-PA infections. Multivariate analysis was performed to identify independent risk factors. Results: A total of 86 cases and 212 controls were included in the study. A logistic regression model showed that exposure to β-lactams [odds ratio (OR) 3.21; 95% confidence interval (CI) 1.74–5.93] or fluoroquinolones (OR 3.50; 95% CI 1.46–8.37) was associated with MBL-PA infections. Other independent risk factors were neurological disease (OR 3.00; 95% CI 1.61–5.58), urinary tract infection (OR 2.48; 95% CI 1.21–5.09) and renal failure (OR 2.29; 95% CI 1.13–4.65). Admission to hospital 1 (OR 5.97; 95% CI 3.45–14.09) and intensive care unit stay (OR 2.07; 95% CI 1.46–3.96) were also associated with increased risk for MBL-PA infections. Conclusions: β-Lactam exposure is an important risk factor for MBL-PA infections even in a setting where patient-to-patient transmission plays a major role in the spread of the isolates. Other risk factors deserve further investigation, particularly exposure to fluoroquinolones.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>16895936</pmid><doi>10.1093/jac/dkl327</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0305-7453 |
ispartof | Journal of antimicrobial chemotherapy, 2006-10, Vol.58 (4), p.882-885 |
issn | 0305-7453 1460-2091 |
language | eng |
recordid | cdi_proquest_miscellaneous_68838664 |
source | Oxford Journals Online |
subjects | Adult Aged Anti-Bacterial Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents bacterial drug resistance beta-Lactamases - biosynthesis beta-Lactams - therapeutic use Biological and medical sciences Case-Control Studies Cross Infection - drug therapy Cross Infection - epidemiology Cross Infection - microbiology Female fluoroquinolones Fluoroquinolones - therapeutic use Hospitals, Teaching Humans Incidence Male Medical sciences Middle Aged multiple bacterial drug resistance P. aeruginosa Pharmacology. Drug treatments Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - enzymology Pseudomonas Infections - drug therapy Pseudomonas Infections - epidemiology Pseudomonas Infections - microbiology Risk Factors SPM-1 β-lactamase β-lactamases |
title | Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-β-lactamase in two tertiary-care teaching hospitals |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T23%3A43%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20for%20nosocomial%20infections%20due%20to%20Pseudomonas%20aeruginosa%20producing%20metallo-%CE%B2-lactamase%20in%20two%20tertiary-care%20teaching%20hospitals&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Zavascki,%20Alexandre%20Prehn&rft.date=2006-10-01&rft.volume=58&rft.issue=4&rft.spage=882&rft.epage=885&rft.pages=882-885&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dkl327&rft_dat=%3Cproquest_pubme%3E68838664%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-i308t-49c934637b9a38ae171e11a3b4e0fe0ba3218286bc7a99343318d1d728ffbb9f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19322172&rft_id=info:pmid/16895936&rfr_iscdi=true |